Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer
Authors:
- 1 May 2015
- journal article
- research article
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 400 (4) , 477-485
Abstract
Much attention has been paid to preoperative treatment as a new strategy especially for borderline resectable pancreatic cancer (BRPC). The purpose of this study was to define the optimal indication of neoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer.Keywords
This publication has 43 references indexed in Scilit:
- Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic CancerAnnals of Surgery, 2015
- Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?The Oncologist, 2014
- Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 StudyJournal of Clinical Oncology, 2014
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial DesignAnnals of Surgical Oncology, 2013
- Pathological and clinical impact of neoadjuvant chemoradiotherapy using full‐dose gemcitabine and concurrent radiation for resectable pancreatic cancerJournal of Hepato-Biliary-Pancreatic Sciences, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic CancerWorld Journal of Surgery, 2011
- Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5‐fluorouracil, and cisplatin followed by radiotherapy and 5‐fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinomaJournal of Surgical Oncology, 2010
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000